Kamada (KMDA) Expected to Announce Earnings on Wednesday

Kamada (NASDAQ:KMDA) is expected to be posting its quarterly earnings results before the market opens on Wednesday, March 5th. Analysts expect Kamada to post earnings of $0.05 per share and revenue of $146.55 million for the quarter.

Kamada Price Performance

Shares of KMDA opened at $7.02 on Wednesday. The firm has a market cap of $403.51 million, a P/E ratio of 25.07, a P/E/G ratio of 0.97 and a beta of 0.99. The stock has a 50 day simple moving average of $6.96 and a two-hundred day simple moving average of $6.08. Kamada has a 1 year low of $4.74 and a 1 year high of $9.15.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $11.00 target price on shares of Kamada in a research note on Friday, January 10th.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.